TY-JUR T1 - 次莫西甲克星和左氧氟沙星治疗多药抗性结核病患者的药物暴露：中国欧洲呼吸杂志JO - EUR RESPIR J DO - 10.118363-2020 VL - 57是 -3 SP - 2003463 AU - 戴维斯Forsman，Lina Au - Niward，Katarina Au - Kuhlin，Johanna Au - Zheng，Xubin Au - Zheng，Rongrong Au - Ke，Ran Au - Hong，Chao Au - Werngren，Jim Au - Pae，JakobAU - Simonsson, Ulrika S.H. AU - Eliasson, Erik AU - Hoffner, Sven AU - Xu, Biao AU - Alffenaar, Jan-Willem AU - Schön, Thomas AU - Hu, Yi AU - Bruchfeld, Judith Y1 - 2021/03/01 UR - //www.qdcxjkg.com/content/57/3/2003463.abstract N2 - Adequate drug exposure is important to ensure tuberculosis (TB) treatment efficacy and to avoid acquired drug resistance. Although low drug exposure has been reported for most anti-TB drugs, data on drug exposure in relation to minimum inhibitory concentration (MIC) are scarce [1, 2]. A fluoroquinolone is a cornerstone in the treatment of multidrug-resistant (MDR)-TB, which results when Mycobacterium tuberculosis is resistant to rifampicin and isoniazid. The activity of fluoroquinolones is best described by the area under the concentration–time curve based on free drug in relation to MIC (fAUC/MIC) [3, 4].This study found target attainment of 0–55% for patients with multidrug-resistant TB using currently recommended doses of moxifloxacin (55%) and levofloxacin (0%), meaning increased doses should be considered to ensure efficacy, if safety can be assured https://bit.ly/3juED6SWe thank the patients for their participation and Brian Davies for language revision. ER -